Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| CS5001NCT05279300 | CStone PharmaceuticalsPHASE1 | SUSPENDED The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| SN514-066bNCT06628037 | SERDA bvPHASE1, PHASE2 | SUSPENDED Administrative Pause- NOT for Safety Reasons | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| DocetaxelNCT01810913 | National Cancer Institute (NCI)PHASE2, PHASE3 | SUSPENDED Other - Assessing accrual feasibility | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| CisplatinNCT01810913 | National Cancer Institute (NCI)PHASE2, PHASE3 | SUSPENDED Other - Assessing accrual feasibility | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| CetuximabNCT01810913 | National Cancer Institute (NCI)PHASE2, PHASE3 | SUSPENDED Other - Assessing accrual feasibility | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| AtezolizumabNCT01810913 | National Cancer Institute (NCI)PHASE2, PHASE3 | SUSPENDED Other - Assessing accrual feasibility | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| CannabisNCT05563948 | New York State Psychiatric InstitutePHASE2 | SUSPENDED In response to quality assurance and compliance concerns, OHRP issued an FWA restriction on NYSPI research that included a pause of human research as of June 23, 2023. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| PaclitaxelNCT03604991 | National Cancer Institute (NCI)PHASE2, PHASE3 | SUSPENDED End of Initial Phase of Multi-phase protocol | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| NivolumabNCT03604991 | National Cancer Institute (NCI)PHASE2, PHASE3 | SUSPENDED End of Initial Phase of Multi-phase protocol | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| IpilimumabNCT03604991 | National Cancer Institute (NCI)PHASE2, PHASE3 | SUSPENDED End of Initial Phase of Multi-phase protocol | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| CarboplatinNCT03604991 | National Cancer Institute (NCI)PHASE2, PHASE3 | SUSPENDED End of Initial Phase of Multi-phase protocol | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| CannabisNCT03766971 | New York State Psychiatric InstitutePHASE2 | SUSPENDED In response to quality assurance and compliance concerns, OHRP issued an FWA restriction on NYSPI research that included a pause of human research as of June 23, 2023. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| RelatlimabNCT06325683 | National Cancer Institute (NCI)PHASE2 | SUSPENDED Scheduled Interim Monitoring | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| NivolumabNCT06325683 | National Cancer Institute (NCI)PHASE2 | SUSPENDED Scheduled Interim Monitoring | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| LomustineNCT06325683 | National Cancer Institute (NCI)PHASE2 | SUSPENDED Scheduled Interim Monitoring | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| CemiplimabNCT06568172 | National Cancer Institute (NCI)PHASE3 | SUSPENDED Other - Other | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-01 |
| CetuximabNCT07042295 | National Cancer Institute (NCI)PHASE2 | SUSPENDED Other - planned analysis of safety and efficacy data | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-08-31 |
| Amivantamab and Recombinant Human HyaluronidaseNCT07042295 | National Cancer Institute (NCI)PHASE2 | SUSPENDED Other - planned analysis of safety and efficacy data | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-08-31 |
| Ga-68-DOTATOCNCT04298541 | Weill Medical College of Cornell UniversityPHASE2 | WITHDRAWN Funding has not been solidified for the initiation of the study. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-08-31 |
| Ga-68- DOTATATENCT04298541 | Weill Medical College of Cornell UniversityPHASE2 | WITHDRAWN Funding has not been solidified for the initiation of the study. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-08-31 |
| FludrocortisoneNCT00368381 | CAMC Health SystemPHASE4 | WITHDRAWN Study closed for PI failure to submit renewal paperwork | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-08-31 |
| HydrocortisoneNCT00368381 | CAMC Health SystemPHASE4 | WITHDRAWN Study closed for PI failure to submit renewal paperwork | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-08-31 |
| Ciprofloxacin plus metronidazoleNCT07625267 | Montefiore Medical CenterPHASE4 | WITHDRAWN Study was never approved by the institutional review board. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-08-31 |
| Amoxicillin-clavulanateNCT07625267 | Montefiore Medical CenterPHASE4 | WITHDRAWN Study was never approved by the institutional review board. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-08-31 |
| Symptomatic treatment (ibuprofen and acetaminophen)NCT07625267 | Montefiore Medical CenterPHASE4 | WITHDRAWN Study was never approved by the institutional review board. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-08-31 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |